Results 131 to 140 of about 28,869 (265)

Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide–Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196

Journal of Acquired Immune Deficiency Syndromes
Supplemental Digital Content is Available in the Text. Background: Switching to the 2-drug regimen dolutegravir (DTG)/lamivudine (3TC) demonstrated durable noninferior efficacy vs continuing 3- or 4-drug tenofovir alafenamide–based regimens for ...
Stéphane De Wit, Fabrice Bonnet, O. Osiyemi, F. Bisshop, Julián Olalla, J. Routy, C. Wyen, Riya Moodley, K. Pappa, Ruolan Wang, J. Oyee, Parminder Saggu, Emilio Letang, B. Wynne, B. Jones, Kimberly Smith, M. Ait-Khaled   +16 more
semanticscholar   +1 more source

Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Late-Presenting People With HIV-1 Infection

Open Forum Infectious Diseases
Background The efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) have been demonstrated in treatment-naive clinical trials.
Xiaoyan Yang, Xiaoxin Xie, Yanhua Fu, Linguang Gan, Shujing Ma, Hai Long   +5 more
semanticscholar   +1 more source

Late HIV Diagnosis but Earlier Antiretroviral Treatment Initiation in Northwest Spain: Impact of Current Treatment Guidelines [PDF]

, 2019
[Abstract] Background: Current HIV treatment guidelines recommend antiretroviral treatment (ART) initiation for all HIV-infected individuals regardless of CD4 count.
Balboa Barreiro, Vanesa, Castro-Iglesias, Ángeles, Cid-Silva, Purificación, Margusino-Framiñán, Luis, Martín-Herranz, Isabel, Mena, Álvaro, Pernas, Berta, Poveda, Eva   +7 more
core   +1 more source

Switching to Tenofovir Therapy Versus Continuation of Entecavir for Patients With Hepatitis B Virus Infection: A Systematic Review and Meta‐Analysis

JGH Open
Background Hepatitis B virus (HBV) infection causes liver disease, including hepatocellular carcinoma. Controlling viral activity is crucial to reducing complications.
Muhammad Shahzil, Ammad Javaid Chaudhary, Talha Kashif, Ali Akram Qureshi, Anza Muhammad, Faiza Khan, Muhammad Saad Faisal, Muhammad Ali Khaqan, Hassam Ali, Yara Dababneh, Dilip Moonka   +10 more
doaj   +1 more source

Distal renal tubular acidosis without renal impairment after use of tenofovir: a case report [PDF]

, 2016
Kentaro Iwata, Manabu Nagata, Shinichi Nishi, Shuhei Watanabe   +3 more
core   +1 more source

The Cost-Effectiveness of Tenofovir Alafenamide for Chronic Hepatitis B Virus in Taiwan

MDM Policy & Practice
Background. Chronic hepatitis B (CHB) is a lifelong disease requiring long-term or indefinite therapy, resulting in substantial economic burden. Thus, careful consideration must be used in the selection of therapies. Aim.
Elise Chia-Hui Tan, Alon Yehoshua, Sushanth Jeyakumar, Pongo Peng, Amy Lin, Nathaniel J. Smith, Nandita Kachru   +6 more
doaj   +1 more source

Gene Discovery and Data Sharing in Genome Wide Association Analyses: Lessons Form AIDS Genetic Restriction Genes [PDF]

, 2014
As genome wide association studies plus whole genome sequence analyses for complex human disease determinants are expanding, it seems useful to develop strategies to facilitate large data sharing, rapid replication and validation of provocative ...
Cherkasov, Nikolay, Dobrynin, Pavel, Geerts, Paul, Hendrickson, Sher L., Hutcheson, Holli, Malov, Sergey, O\u27Brien, Stephen J., Sezgin, Efe, Svitin, Anton, Troyer, Jennifer L.   +9 more
core   +1 more source

Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial [PDF]

, 2018
BACKGROUND: Weekends off antiretroviral therapy (ART) may help engage HIV-1-infected young people facing lifelong treatment. BREATHER showed short cycle therapy (SCT; 5 days on, 2 days off ART) was non-inferior to continuous therapy (CT) over 48 weeks ...
Babiker, A, Bologna, R, BREATHER (PENTA 16) Trial Group, ., Bunupuradah, T, Butler, K, Chalermpantmetagul, S, Compagnucci, A, Cressey, TR, Flynn, PM, Ford, D, Giaquinto, C, Gibb, DM, Harper, L, Kaudha, E, Klein, N, Montero, S, Moore, CL, Musiime, V, Nanduudu, A, Nastouli, E, Ramos Amador, JT, Riault, Y, Saïdi, Y, Scott, K, Turkova, A, Volokha, A, Welch, SB   +26 more
core  

Tenofovir is associated with increased tubular proteinuria and asymptomatic renal tubular dysfunction in Ghana [PDF]

, 2015

core   +1 more source

Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study

Health Science Reports
Background and Aims People living with human immunodeficiency virus (HIV, PLWH) are aging, and there are growing concerns regarding combined antiretroviral therapy (cART)‐associated negative metabolic consequences.
Ping‐Feng Wu, Hsi‐Hsun Lin, Hsin‐Pai Chen, Po‐Chieh Huang, Meng‐Yu Ke   +4 more
doaj   +1 more source